Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek™), in the management of malignancy-associated hyperuricemia in pediatric and adult patients:: final results of a multicenter compassionate use trial

被引：115
作者：
Jeha, S
Kantarjian, H
Irwin, D
Shen, V
Shenoy, S
Blaney, S
Camitta, B
Pui, CH
机构：
[1] St Jude Childrens Res Hosp, Memphis, TN 38105 USA
[2] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Alta Bates Comprehens Canc Ctr, Berkeley, CA USA
[4] Childrens Hosp Orange Cty, Orange, CA 92668 USA
[5] Washington Univ, Sch Med, St Louis, MO USA
[6] Texas Childrens Canc Ctr, Houston, TX USA
[7] Med Coll Wisconsin, Midw Childrens Canc Ctr, Milwaukee, WI 53226 USA
来源：
LEUKEMIA | 2005年 / 19卷 / 01期
关键词：
tumor lysis; hyperuricemia; uric acid; urate oxidase; Rasburicase; Elitek (TM);
D O I：
10.1038/sj.leu.2403566
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The recombinant urate oxidase, rasburicase (Elitekt(TM), Sanofi-Synthelabo, Inc.), has recently received regulatory approval for the prevention and treatment of hyperuricemia in children with leukemia, lymphoma, and solid tumors. Prior to approval, 682 children and 387 adults in the US and Canada received rasburicase on compassionate-use basis. Uric acid concentration declined rapidly in both adult and pediatric patients after rasburicase treatment. Similar responses were observed in patients treated with subsequent courses. Possible drug-related adverse events, including allergic reactions, were uncommon. These data confirm that rasburicase is effective and safe for the treatment and prophylaxis of children and adults with malignancy-associated hyperuricemia.
引用
收藏
页码：34 / 38
页数：5
相关论文
共 20 条
[1]   PURINE EXCRETION DURING TUMOR LYSIS IN CHILDREN WITH ACUTE LYMPHOCYTIC-LEUKEMIA RECEIVING ALLOPURINOL - RELATIONSHIP TO ACUTE-RENAL-FAILURE [J].
ANDREOLI, SP ;
CLARK, JH ;
MCGUIRE, WA ;
BERGSTEIN, JM .
JOURNAL OF PEDIATRICS, 1986, 109 (02) :292-298
[2]   Improved cure rate in children with B-cell acute lymphoblastic leukaemia (B-ALL) and stage IV B-cell non Hodgkin's lymphoma (B-NHL) - results of the UKCCSG 9003 protocol [J].
Atra, A ;
Gerrard, M ;
Hobson, R ;
Imeson, JD ;
Ashley, S ;
Pinkerton, CR .
BRITISH JOURNAL OF CANCER, 1998, 77 (12) :2281-2285
[3]   Acute tumor lysis syndrome in solid tumors - a case report and review of the literature [J].
Baeksgaard, L ;
Sorensen, JB .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 51 (03) :187-192
[4]   XANTHINE NEPHROPATHY IN A PATIENT WITH LYMPHOSARCOMA TREATED WITH ALLOPURINOL [J].
BAND, PR ;
SILVERBERG, DS ;
HENDERSON, JF ;
ULAN, RA ;
WENSEL, RH ;
BANERJEE, TK ;
LITTLE, AS .
NEW ENGLAND JOURNAL OF MEDICINE, 1970, 283 (07) :354-+
[5]   Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer - Report of an international compassionate use study [J].
Bosly, A ;
Sonet, A ;
Pinkerton, CR ;
McCowage, G ;
Bron, D ;
Sanz, MA ;
Van den Berg, H .
CANCER, 2003, 98 (05) :1048-1054
[6]   Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: A pediatric oncology group study [J].
Bowman, WP ;
Shuster, JJ ;
Cook, B ;
Griffin, T ;
Behm, F ;
Pullen, J ;
Link, M ;
Head, D ;
Carroll, A ;
Berard, C ;
Murphy, S .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (04) :1252-1261
[7]  
CHOUKAIR MK, 1996, H LANE HDB MANUAL PE, P119
[8]   USE OF ALLOPURINOL FOR PREVENTION AND CONTROL OF HYPERURICEMIA IN PATIENTS WITH NEOPLASTIC DISEASE [J].
DECONTI, RC ;
CALABRESI, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1966, 274 (09) :481-+
[9]   A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis [J].
Goldman, SC ;
Holcenberg, JS ;
Finklestein, JZ ;
Hutchinson, R ;
Kreissman, S ;
Johnson, FL ;
Tou, C ;
Harvey, E ;
Morris, E ;
Cairo, MS .
BLOOD, 2001, 97 (10) :2998-3003
[10]   URINARY XANTHINE STONES - A RARE COMPLICATION OF ALLOPURINOL THERAPY [J].
GREENE, ML ;
FUJIMOTO, WY ;
SEEGMILLER, JE .
NEW ENGLAND JOURNAL OF MEDICINE, 1969, 280 (08) :426-+
12